Understanding Type 2 Inflammation

PayerTalkCE® Presents: Understanding Type 2 Inflammation: Atopic Dermatitis

Track 1 - Spotlight on Atopic Dermatitis
Track 2 - Best Practices in Atopic Dermatitis Management

• Release Date: January 31, 2025
• Expiration Date: July 31, 2026
• Estimated Time to Complete Activity: 0.75 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty

Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography Shawn G. Kwatra, MD Chair, Department of Dermatology and Chief of Service of Dermatology University of Maryland Medical Center (UMMC) Click here for biography Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
• Summarize safety and efficacy of treatments for patients with atopic dermatitis
• Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates each continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-013-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-014-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.75 contact hour.

Track 1: Spotlight on Atopic Dermatitis – 0.75 contact hour
Track 2: Best Practices in Atopic Dermatitis Management – 0.75 contact hour

DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Name of Working Group Members/Planners	Reported Financial Relationship
Dana McCormick, RPh, FAMCP	Nothing to report.
Shawn G. Kwatra, MD	Nothing to report.
Drake Reiter, PharmD	Nothing to report.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

PayerTalkCE® Presents: Understanding T2 Inflammation: Atopic Dermatitis

Track 1 - Spotlight on Atopic Dermatitis Infographic
Track 2 - Best Practices in Atopic Dermatitis Management Infographic

• Release Date: January 31, 2025
• Expiration Date: July 31, 2026
• Estimated Time to Complete Activity: 0.5 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters

Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography Shawn G. Kwatra, MD Chair, Department of Dermatology and Chief of Service of Dermatology University of Maryland Medical Center (UMMC) Click here for biography Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
• Summarize safety and efficacy of treatments for patients with atopic dermatitis
• Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates each continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-017-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-018-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.

Track 1: Spotlight on Atopic Dermatitis Infographic – 0.5 contact hour
Track 2: Best Practices in Atopic Dermatitis Management Infographic – 0.5 contact hour

DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Name of Working Group Members/Planners	Reported Financial Relationship
Dana McCormick, RPh, FAMCP	Nothing to report.
Shawn G. Kwatra, MD	Nothing to report.
Drake Reiter, PharmD	Nothing to report.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

PayerTalkCE® Presents: Understanding Type 2 Inflammation: Moderate-to-Severe Asthma

Track 1 - Spotlight on Moderate-to-Severe Asthma
Track 2 - Best Practices in Moderate-to-Severe Asthma Management

• Release Date: March 1, 2025
• Expiration Date: August 31, 2026
• Estimated Time to Complete Activity: 0.75 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty

Jeffrey D. Dunn, PharmD, MBA President and Chief Executive Officer Cooperative Benefits Group (CBG) Click here for biography Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield Of Michigan Lecturer Jefferson College of Population Health Click here for biography Anju T. Peters, MD, MSCI, FAAAAI Professor of Medicine Director of Clinical Research Division of Allergy/Immunology and Otolaryngology Northwestern University Feinberg School of Medicine Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
T2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease. Managed care professionals require education regarding T2 inflammation pathways in asthma and comorbidities as well as the safety and efficacy of treatments used to manage patients with moderate-to-severe asthma. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with moderate-to-severe asthma.

Educational Objectives
After completing this activity, the participant should be better able to:

• Explain how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
• Review safety and efficacy of pharmaceuticals targeting T2 inflammation in moderate-to-severe asthma
• Cite payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-069-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-070-H01-P- 0.75 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

Track 1: Spotlight on Moderate-to=Severe Asthma – 0.75 contact hour
Track 2: Best Practices in Moderate-to=Severe Asthma Management – 0.75 contact hour

DISCLOSURE OF CONFLICTS OF INTEREST

Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Name of Working Group Members/Planners	Reported Financial Relationship
Jeffrey D. Dunn, PharmD, MBA	Faculty for this activity, has no relevant financial relationships.
Michael Kobernick, MD, MS, MS-PopH, CPE	Faculty for this activity, has no relevant financial relationships.
Anju T. Peters, MD, MSCI, FAAAAI	Faculty for this activity, has the following relevant financial relationships: Researcher for Astra Zeneca, Sanofi Regeneron Independent Contractor for Astra Zeneca, Chiesi, Eli Lilly, GSK, Merck, Sanofi Regeneron

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

Understanding T2 Inflammation: Moderate-to-Severe Asthma

Track 1 - Spotlight on Moderate-to-Severe Asthma Infographic
Track 2 - Best Practices in Moderate-to-Severe Asthma Management Infographic

• Release Date: March 1, 2025
• Expiration Date: August 31, 2026
• Estimated Time to Complete Activity: 0.5 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty

Jeffrey D. Dunn, PharmD, MBA President and Chief Executive Officer Cooperative Benefits Group (CBG) Click here for biography Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield Of Michigan Lecturer Jefferson College of Population Health Click here for biography Anju T. Peters, MD, MSCI, FAAAAI Professor of Medicine Director of Clinical Research Division of Allergy/Immunology and Otolaryngology Northwestern University Feinberg School of Medicine Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
T2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease. Managed care professionals require education regarding T2 inflammation pathways in asthma and comorbidities as well as the safety and efficacy of treatments used to manage patients with moderate-to-severe asthma. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with moderate-to-severe asthma.

Educational Objectives
After completing this activity, the participant should be better able to:

• Explain how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
• Review safety and efficacy of pharmaceuticals targeting T2 inflammation in moderate-to-severe asthma
• Cite payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates each continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-084-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-085-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.

Track 1: Spotlight on Moderate-to-Severe Asthma – 0.5 contact hour
Track 2: Best Practices in Moderate-to-Severe Asthma Management – 0.5 contact hour

DISCLOSURE OF CONFLICTS OF INTEREST
Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Name of Working Group Members/Planners	Reported Financial Relationship
Jeffrey D. Dunn, PharmD, MBA	Faculty for this activity, has no relevant financial relationships.
Michael Kobernick, MD, MS, MS-PopH, CPE	Faculty for this activity, has no relevant financial relationships.
Anju T. Peters, MD, MSCI, FAAAAI	Faculty for this activity, has the following relevant financial relationships: Researcher for Astra Zeneca, Sanofi Regeneron Independent Contractor for Astra Zeneca, Chiesi, Eli Lilly, GSK, Merck, Sanofi Regeneron

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

PayerTalkCE® Present: Understanding T2 Inflammation: Spotlight on COPD

Track 1 - Understanding T2 Inflammation: Spotlight on COPD
Track 2 - Understanding T2 Inflammation: Best Practices in COPD Management

• Release Date: May 1, 2025
• Expiration Date: November 30, 2026
• Estimated Time to Complete Activity: 0.75 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters

Jeffrey D. Dunn, PharmD, MBA President and Chief Executive Officer Cooperative Benefits Group (CBG) Click here for biography MeiLan Han, MD, MS Professor of Medicine Chief of the Division of Pulmonary and Critical Care University of Michigan Health Click here for biography Matthew Harman, PharmD, MPH VP of Clinical Solutions Employers Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Type 2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in COPD, as well as the presence of comorbid disease. Managed care professionals will benefit from education regarding T2 inflammation pathways in COPD and comorbidities as well as the safety and efficacy of treatments used to manage patients with COPD. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with COPD.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities
• Summarize safety and efficacy for biologics used to manage patients with COPD
• Assess payer care management initiatives and other opportunities to improve the quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-139-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-140-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

Track 1: Spotlight on COPD – 0.75 contact hour
Track 2: Best Practices in COPD Management – 0.75 contact hour

DISCLOSURE OF CONFLICTS OF INTEREST

Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Jeffrey D. Dunn, PharmD, MBA, faculty for this activity, has no relevant financial relationships.

MeiLan Han, MD, MS: faculty for this activity, has the following relevant financial relationships: Consultant, Advisor, Speaker: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, Roche, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Owkin, Medscape, NACE, MDBriefcase, Integrity and Medwiz Researcher: NIH, Novartis, Sunovion, Nuvaira, Sanofi, Astrazeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association DSMB, funds paid to institution: Novartis and Medtronic Stock options: Meissa Vaccines and Altesa Biopharma

Matthew Harman, PharmD, MPH, faculty for this activity, has the following relevant financial relationships: Consultant, Advisor, Speaker: GSK, Novo Nordisk

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

PayerTalkCE® Presents: Understanding T2 Inflammation: COPD

Track 1 - Understanding T2 Inflammation: Spotlight on COPD Infographic
Track 2 - Understanding T2 Inflammation: Best Practices in COPD Management Infographic

• Release Date: May 1, 2025
• Expiration Date: November 30, 2026
• Estimated Time to Complete Activity: 0.5 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters

Jeffrey D. Dunn, PharmD, MBA President and Chief Executive Officer Cooperative Benefits Group (CBG) Click here for biography MeiLan Han, MD, MS Professor of Medicine Chief of the Division of Pulmonary and Critical Care University of Michigan Health Click here for biography Matthew Harman, PharmD, MPH VP of Clinical Solutions Employers Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Type 2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in COPD, as well as the presence of comorbid disease. Managed care professionals will benefit from education regarding T2 inflammation pathways in COPD and comorbidities as well as the safety and efficacy of treatments used to manage patients with COPD. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with COPD.

Educational Objectives
After completing this activity, the participant should be better able to:

Track 1:

• Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities

Track 2:

• Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities
• Assess payer care management initiatives and other opportunities to improve the quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare.

Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-139-H01-P- 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: - JA4008073-9999-25-140-H01-P- 0.5 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Track 1: Spotlight on COPD – 0.5 contact hour
Track 2: Best Practices in COPD Management – 0.5 contact hour

DISCLOSURE OF CONFLICTS OF INTEREST

Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Jeffrey D. Dunn, PharmD, MBA, faculty for this activity, has no relevant financial relationships.

MeiLan Han, MD, MS: faculty for this activity, has the following relevant financial relationships: Consultant, Advisor, Speaker: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, Roche, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Owkin, Medscape, NACE, MDBriefcase, Integrity and Medwiz Researcher: NIH, Novartis, Sunovion, Nuvaira, Sanofi, Astrazeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association DSMB, funds paid to institution: Novartis and Medtronic Stock options: Meissa Vaccines and Altesa Biopharma

Matthew Harman, PharmD, MPH, faculty for this activity, has the following relevant financial relationships: Consultant, Advisor, Speaker: GSK, Novo Nordisk

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.